IL6 and lung cancer: The decreased levels of inflammatory factors (IL-6, IL-8, and TNF-α) strongly associated with curcumin administration (180 mg/day; ~cmax 0.5 μmol/l in human plasma [151]) in patients with cancer, including those with lung cancer [119], imply a possible reduction of the M2 TAM phenotype.